Currently out of the existing stock ratings of Jami Rubin, 41 are a BUY (62.12%), 17 are a HOLD (25.76%), 8 are a SELL (12.12%).

Jami Rubin

Work Performance Price Targets & Ratings Chart

Analyst Jami Rubin, carries an average stock price target met ratio of 82.69% that have a potential upside of 31.24% achieved within 538 days. Previously, Jami Rubin worked at GOLDMAN SACHS.

Jami Rubin’s has documented 145 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.

Wall Street Analyst Jami Rubin

Analyst best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 11/6/2017. The price target of $13 was fulfilled within 11 days with a profit of $0.67 (5.43%) receiving and performance score of 4.94.

Average potential price target upside

of $44.72 (76.84%) on ABBV (ABBVIE).
of $22.56 (25.31%) on JNJ (JOHNSON & JOHNSON).
of $21.95 (56.83%) on BMY (BRISTOL-MYERS SQUIBB COMPANY).

ABBV AbbVie AGN Allergan plc BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany MYL Viatris PRGO Perrigo Company PLC TEVA Teva Pharma Industries Ltd ADR LLY Eli Lilly and Company PFE Pfizer VTRS Viatris ALNY Alnylam Pharmaceuticals ZTS Zoetis

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Vamil Divan (GUGGENHEIM)